Acute Promyelocytic Leukemia Clinical Trial
Official title:
Risk-stratified Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia
Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. We have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients. Furthermore, in an effort to prevent relapse, we have moved oral-As2O3 forward to the maintenance of CR1. This strategy results in favorable overall-survival (OS) and leukemia-free-survival (LFS), implying that prolonged treatment with oral-As2O3 may prevent relapses. Current protocols have incorporated i.v.-As2O3 in the treatment of newly-diagnosed APL. In regimens comprising i.v.-As2O3, ATRA and chemotherapy, 5-year overall survivals in excess of 90% is achieved. In this study, we evaluate the use of oral-As2O3 and ATRA based induction regimens in newly diagnosed patients with APL. In this study, we evaluate the efficacy and tolerability of frontline oral arsenic trioxide-based regimen in newly diagnosed patients with acute promyelocytic leukaemia
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00520208 -
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
|
Phase 2 | |
| Suspended |
NCT04996030 -
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT02899169 -
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
|
Phase 3 | |
| Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
| Recruiting |
NCT04793919 -
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02938858 -
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
|
N/A | |
| Recruiting |
NCT02991066 -
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
|
||
| Terminated |
NCT00985530 -
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
|
Phase 1 | |
| Withdrawn |
NCT00670150 -
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT01064570 -
AIDA 2000 Guidelines
|
Phase 2 | |
| Completed |
NCT01472107 -
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
|
||
| Active, not recruiting |
NCT03096496 -
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
|
||
| Completed |
NCT00465933 -
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
|
Phase 4 | |
| Active, not recruiting |
NCT02688140 -
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
|
Phase 3 | |
| Active, not recruiting |
NCT01987297 -
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
|
Phase 4 | |
| Terminated |
NCT00907582 -
ASCT for Relapsed APL After Molecular Remission
|
Phase 2 | |
| Recruiting |
NCT00517712 -
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
|
Phase 2/Phase 3 | |
| Completed |
NCT01902329 -
A Safety Study of SGN-CD33A in AML Patients
|
Phase 1 | |
| Completed |
NCT01404949 -
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
|
Phase 2 | |
| Completed |
NCT00504764 -
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
|
Phase 4 |